{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:30:49Z","timestamp":1790109049790,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015091","name":"NIHR Collaboration for Leadership in Applied Health Research and Care South London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia. The aim of the current study was to evaluate the relationship between serum prolactin (PRL) concentrations and prolactinoma size, and to determine a cut-off PRL value that could differentiate micro- from macro-prolactinomas. A retrospective cohort study of 114 patients diagnosed with prolactinomas between 2007 and 2017 was conducted. All patients underwent gadolinium enhanced pituitary MRI and receiver operating characteristic (ROC) analyses were performed. 51.8% of patients in this study were men, with a mean age at the time of diagnosis of 42.32\u2009\u00b1\u200915.04\u00a0years. 48.2% of the total cohort were found to have microadenomas. Baseline serum PRL concentrations were strongly correlated to tumour dimension (r\u2009=\u20090.750, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). When performing the ROC curve analysis, the area under the curve was 0.976, indicating an excellent accuracy of the diagnostic method. For a value of 204\u00a0\u03bcg\/L (4338\u00a0mU\/L), sensitivity and specificity were calculated at 0.932 and 0.891, respectively. When a cut off value of 204\u00a0\u03bcg\/L (4338\u00a0mU\/L) was used, specificity was 93.2%, and sensitivity 89.1%, acceptable to reliably differentiate between micro- and macro- adenomas.<\/jats:p>","DOI":"10.1038\/s41598-021-89256-7","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T10:12:23Z","timestamp":1620382343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Bianca M.","family":"Leca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mytilinaiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tsoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Epure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J. B.","family":"Aylwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpal S.","family":"Randeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-804X","authenticated-orcid":false,"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"1","key":"89256_CR1","first-page":"3","volume":"39","author":"M Saleem","year":"2018","unstructured":"Saleem, M., Martin, H. & Coates, P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin. Biochem. Rev. 39(1), 3\u201316 (2018).","journal-title":"Clin. Biochem. Rev."},{"key":"89256_CR2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm8122203","volume":"8","author":"I Samperi","year":"2019","unstructured":"Samperi, I., Lithgow, K. & Karavitaki, N. Hyperprolactinaemia. J. Clin. Med. 8, 2203 (2019).","journal-title":"J. Clin. Med."},{"issue":"2","key":"89256_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-3997000000032","volume":"62","author":"L Vilar","year":"2018","unstructured":"Vilar, L. et al. Controversial issues in the management of hyperprolactinemia and prolactinomas\u2014an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch. Endocrinol. Metab. 62(2), 236\u2013263 (2018).","journal-title":"Arch. Endocrinol. Metab."},{"issue":"1","key":"89256_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","volume":"44","author":"A Glezer","year":"2015","unstructured":"Glezer, A. & Bronstein, M. D. Prolactinomas. Endocrinol. Metab. Clin. N. Am. 44(1), 71\u201378 (2015).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"89256_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. JCEM 96, 273\u2013288 (2011).","journal-title":"JCEM"},{"issue":"3","key":"89256_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11102-014-0576-7","volume":"18","author":"MB Whyte","year":"2015","unstructured":"Whyte, M. B. et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18(3), 319\u2013325 (2015).","journal-title":"Pituitary"},{"issue":"13","key":"89256_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"Klibanski, A. Clinical practice .Prolactinomas [published correction appears in N Engl J Med. 2010 Jun 3;362(22):2142]. N. Engl. J. Med. 362(13), 1219\u20131226 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"89256_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","volume":"60","author":"HI Rabinovich","year":"2013","unstructured":"Rabinovich, H. I., G\u00f3mez, C. R., Mouriz, G. M. & Garc\u00eda-Agull\u00f3, O. D. Grupo de Trabajo de Neuroendocrinolog\u00eda de la SEEN. Gu\u00eda cl\u00ednica de diagn\u00f3stico y tratamiento del prolactinoma y la hiperprolactinemia [Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia]. Endocrinol Nutr. 60(6), 308\u2013319 (2013).","journal-title":"Endocrinol Nutr."},{"key":"89256_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar, L. et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest. 31, 436\u2013444 (2008).","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"89256_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5603\/EP.2014.0029","volume":"65","author":"S Cander","year":"2014","unstructured":"Cander, S., G\u00fcl, \u00d6. \u00d6., Ert\u00fcrk, E., Tuncel, E. & Ersoy, C. Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not. Endokrynol. Pol. 65(3), 210\u2013216 (2014).","journal-title":"Endokrynol. Pol."},{"key":"89256_CR11","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102\u20132107 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"89256_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00234-002-0774-2","volume":"44","author":"H Nishioka","year":"2002","unstructured":"Nishioka, H., Haraoka, J., Akada, K. & Azuma, S. Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology 44, 407\u2013410 (2002).","journal-title":"Neuroradiology"},{"key":"89256_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh, A., Benbassat, C., Lifshitz, A. & Shimon, I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18, 108\u2013115 (2015).","journal-title":"Pituitary"},{"key":"89256_CR14","first-page":"1","volume":"133","author":"WT Burke","year":"2019","unstructured":"Burke, W. T. et al. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size [published online ahead of print, 2019 Jun 14]. J.. Neurosurg. 133, 1\u20138 (2019).","journal-title":"J.. Neurosurg."},{"key":"89256_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/1756-0500-7-555","volume":"7","author":"T Kawaguchi","year":"2014","unstructured":"Kawaguchi, T., Ogawa, Y. & Tominaga, T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res. Notes. 7, 555 (2014).","journal-title":"BMC Res. Notes."},{"key":"89256_CR16","unstructured":"Bronstein, M.D. Disorders of prolactin secretion and prolactinomas. In: De Groot, L. J and Jameson J. L. (Org.). Endocrinology. 2\u00baed. Vol. 1, 485\u2013510 (Elsevier Saunders, 2010)."},{"issue":"5","key":"89256_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds, R. et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin. Endocrinol. (Oxf.) 90(5), 662\u2013669 (2019).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"5","key":"89256_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2011","unstructured":"Colao, A. & Savastano, S. Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7(5), 267\u2013278 (2011).","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89256-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:46:04Z","timestamp":1670053564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89256-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89256"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89256-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9801"}}